Belgrade 2018 Meeting Highlights Registration Abstract Submission Exhibition Virtual Exhibition Hotel Information Satellite Programme Visa Letter Application

An excimer laser refractive surgical treatment for presbyopia: optics-based customization for improved clinical outcome in myopic patients

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Session Details

Session Title: Refractive
Session Date/Time: Friday 09/02/2018 | 10:30-12:00
Paper Time: 11:18
Venue: Annex A

First Author: B.Pajic SERBIA
Co Author(s): Z. Cvejic  J. Mueller  V. Canadanovic  B. Pajic-Eggspuehler  -0      

Abstract Details


To analyse the clinical outcomes of the Femto-Presbylasik with a multifocal wavefront guided corneal ablation profile


Eye Clinic ORASIS, Swiss Eye Reseach Foundation, Reinach AG, Switzerland


In this study, a novel customization algorithm for designing multifocal ablation patterns, thereby minimizing induced optical aberrations, was used to treat 36 myopic presbyopic subjects with 72 eyes. The uncorrected distance visual acuity (UDVA), uncorrected intermediate visual acuity (UIVA), uncorrected near visual acuity (UNVA), and higher order aberrations were reported from baseline to 6 months.


Results showed that most candidates went from poor visual acuity to uncorrected 20/20 vision or better for near (78%), intermediate (92%), and for distance (86%) vision, six months after surgery. All subjects were at 20/25 or better for distance and intermediate vision, and a majority (94%) were also better for near vision. Fifty-eight out of the 72 eyes had a decreased spherical aberration between 0.21 to 0.40 microns. Nine eyes had a decrease of quadrafoil aberration between 10 and 20 microns, and 62 eyes had a decrease of more than 20 microns of quadrafoil aberration. The spherical (Z400) as well as quadrafoil (Z440) aberrations were significantly reduced by the treatment.


The PresbyLASIK treatment employed in this study a safe procedure and shows reliable, predictable, and satisfying outcomes

Financial Disclosure:


Back to previous